In couples with unexplained or mild male-factor infertility, adding ganirelix did not change clinical pregnancy rates versus FSH alone.
In plain wordsIn couples with unexplained or mild male-factor infertility, adding ganirelix did not change clinical pregnancy rates versus FSH alone.
- Peptide
- Ganirelix
- Outcome
- No significant changeClinical pregnancy rate per initiated cycle
- Study
n = 299
- Comparator
- Recombinant FSH alone
- Analysis
- Primary
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 0.25 mg dailyAs given in this study (human).
Measurements
- Clinical pregnancy rate
- 12.2%
- ganirelix
- Clinical pregnancy rate
- 12.6%
- control
- Relative risk of conception
- 1 ratio
- ganirelix versus control
- Relative risk confidence interval
- 0.5 to 1.9 ratio
- 95% confidence interval
Source sentences
Clinical pregnancy rates per initiated cycle in women who did and did not receive GnRH antagonists were 12.2 and 12.6%, respectively (P=1.00).
4 context sentences(design, population, supporting numbers)
The relative risk of conception (95% confidence interval) for the use of GnRH antagonists was 1.0 (0.5-1.9).
Two-hundred and ninety-nine couples with unexplained or mild male factor infertility were enrolled in this international multicentre randomized controlled trial.
Women allocated to the GnRH antagonist group (n=148) received 50 IU recombinant FSH starting on day 3 of the menstrual cycle and Ganirelix 0.25 mg daily starting from the day in which a follicle with a mean diameter of 13-14 mm was visualized at ultrasound.
Women allocated to the control group (n=151) were administered only 50 IU recombinant FSH starting on day 3 of the menstrual cycle.